A blockbuster anti-obesity and diabetes drug could cost as little as $3 per month to manufacture once it goes off patent later this month, researchers said Friday, providing a major opportunity to boost health in low and middle-income countries.
Semaglutide, the active molecule in Novo Nordisk’s Ozempic and Wegovy treatments, leads to considerable weight-loss in patients and thus can provide major help in managing diabetes and other medical problems related to obesity.
Semaglutide will lose patent protection in countries such as Brazil, China and India later this month, and researchers identified 150 countries where it was never patented.
Using pricing information from other medicines that recently went off patent, researchers in Britain, South Africa and New Zealand calculated the potential generic manufacturing price for semaglutide.
They estimated it will cost as little as $3 to produce a month’s supply of semaglutide, which in its branded form sells for around $200 a month in the United States.
Dr Samuel Cross of Imperial College London, one of the study’s authors, noted that obesity and diabetes are chronic diseases that increase the risk of stroke, diabetes, heart disease, kidney failure and cancer.
“If generic production reduces prices to sustainable levels, millions more people could access treatment,” he said.
Hundreds of millions of people worldwide suffer from Type 2 diabetes, which can lead to kidney failure, blindness and amputation.
Globally, clinical obesity leads to 3.7 million deaths each year.
The researchers estimated that the 160 countries where semaglutide will not be under patent account for 69 per cent of people with Type 2 diabetes globally and 84 per cent of people with clinical obesity.
Another of the study’s authors, Professor Francois Venter at the University of Witwatersrand in South Africa, said drugs to treat HIV, TB, malaria and hepatitis are now available at prices close to production costs but still sufficient for generic manufacturers to operate.
“We can repeat this medical success story for semaglutide,” he said.
The researchers published their research directly and not in a peer-reviewed scientific journal.
Interesting insight it’s amazing to think a life‑changing anti‑obesity treatment might one day cost almost nothing, making healthy living accessible to so many more people worldwide. For anyone curious about today’s most effective weight‑loss medications and how they compare, check out https://southwestweightloss.com/best-weight-loss-medication/
The possibility of lower-cost generic semaglutide could make obesity and diabetes treatment more accessible worldwide, especially in low- and middle-income countries. Expanding access to effective therapies may help reduce long-term health risks linked to these conditions. There’s also useful information about potential pricing changes and patent expirations here: https://www.glp-1pills.com/generic-semaglutide-could-cost-as-little-as-3-per-month-after-patent-expirations-begin/
Lower-cost generic semaglutide could significantly improve access to obesity and diabetes treatment worldwide, especially in lower-income countries. Expanding affordability may help reduce long-term complications linked to these conditions. Research into next-generation therapies is also progressing, including AI-driven approaches discussed here: https://www.pharmacyuk.com/ai-powered-obesity-treatment-candidate-delivers-31-weight-loss-in-early-tests/
.
The potential for semaglutide to cost as little as $3/month to manufacture could be a game-changer for global obesity care, especially in low-income regions where access is limited.
If pricing truly reflects production costs after patents expire, it could significantly reduce the gap between innovation and accessibility.
Interesting perspective here: https://southwestweightloss.com/coupon-codes/ Affordability combined with proper guidance may be key to long-term success.
The possibility of low-cost generic semaglutide could significantly improve access to obesity and diabetes treatment, especially in lower-income regions.
It also highlights the gap between manufacturing costs and current market pricing of branded medications.
For those comparing current pricing structures, this may provide useful context: https://www.pharmacyuk.com/wegovy-price-comparison-uk/
This is really interesting shows how affordable these treatments could become in the future, especially once patents expire.
For anyone looking at current options and providers, this guide might help: https://southwestweightloss.com/comparison/top-rated-foundayo-pill-providers-in-usa/